This week in the Netherlands, several medicines were removed from reimbursement – specifically, PARP inhibitors. We won’t delve into Dutch specifics, but this leads us to ask: When is a medicine of added value, and what criteria should we consider? We were immediately...
On June 10 and 11, Inspire2Live attended the Economist Impact 10th annual World Cancer Series Europe congress: ‘Shaping the cancer-control agenda’. One engaging session explored a crucial question: What should be the priority for the near and distant future? The...
Patient surveys consistently reveal a powerful truth: patients are overwhelmingly willing to share their data—for improvements in care, better treatments, and enhanced quality of life. They don’t just consent to data use; they expect it. They want their data to drive...
Research drives progress in cancer treatment We are aware that research is the driving force behind progress in cancer treatments. Forty years ago, almost all children with leukaemia died. Today, in high-income countries, over 95% of these children survive. This is an...
Confronting difficult questions and situations in cancer care This week, I was confronted once again with a series of difficult questions and situations that affect people living with cancer. I speak not just as an observer, but as someone directly affected — I am a...
